Effect of asimadoline, a κ opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome

Autor:	Jutta Jacob, J. Frexinos, Weber Frank, Michel Delvaux, A. Beck, H. Bouzamondo
Rok vydání:	2004
Předmět:	Abdominal pain Hepatology business.industry Analgesic Gastroenterology Distension medicine.disease Placebo digestive system diseases Opioid Anesthesia Threshold of pain medicine Asimadoline Pharmacology (medical) medicine.symptom business Irritable bowel syndrome medicine.drug
Zdroj:	Alimentary Pharmacology & Therapeutics. 20:237-246
ISSN:	0269-2813
DOI:	10.1111/j.1365-2036.2004.01922.x
Popis:	Summary Background : Visceral hypersensitivity plays a major role in irritable bowel syndrome pathophysiology. Opioid κ receptors on afferent nerves may modulate it and be the target for new irritable bowel syndrome treatments. Aim : This study evaluated the effect of the κ opioid agonist asimadoline on perception of colonic distension and colonic compliance in irritable bowel syndrome patients. Method : Twenty irritable bowel syndrome female patients (Rome II criteria; 40 ± 13 years) and hypersensitivity to colonic distension (Pain threshold ≤32 mmHg) were included in a randomized double-blind cross-over trial comparing the effect of a single oral dose of asimadoline 0.5 mg or placebo on sensory thresholds (defined as a constant and sustained sensation) elicited by left colon phasic distension (5 mmHg steps, 5 min) up to a sensation of abdominal pain. Colonic compliance was compared by the slope of the pressure–volume curves. Results : On asimadoline, pain threshold (mean ± s.d.) (29.8 ± 7.2 mmHg) was higher than on placebo (26.3 ± 7.8 mmHg), difference not statistically significant (P = 0.1756, anova). Area under curve of pain intensity rated at each distension step was significantly lower on asimadoline (89.3 ± 33.9, anova) than on placebo (108.1 ± 29.7) (P = 0.0411). Thresholds of perception of nonpainful distensions were not altered on asimadoline, as compared with placebo. Colonic compliance was not different on placebo and asimadoline. Conclusion : Asimadoline decreases overall perception of pain over a wide range of pressure distension of the colon in irritable bowel syndrome patients, without altering its compliance. These data suggest that further studies should explore the potential benefit of asimadoline in treatment of pain in irritable bowel syndrome patients.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::68d497ddf5273323cd09996deb3bb593 https://doi.org/10.1111/j.1365-2036.2004.01922.x Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.